亚洲轮状病毒疫苗评估——是否有值得借鉴的经验？

Evaluation of rotavirus vaccines in Asia--are there lessons to be learnt?

机构信息

Program for Appropriate Technology in Health (PATH), Ferney-Voltaire, France.

出版信息

Vaccine. 2009 Nov 20;27 Suppl 5:F120-9. doi: 10.1016/j.vaccine.2009.09.039.

DOI:10.1016/j.vaccine.2009.09.039

PMID:19931711

Abstract

Rotavirus mortality is highest in the Asia-Pacific region and rotavirus vaccines could have enormous impact here. Yet, live-attenuated orally administered rotavirus vaccines have been evaluated in a small number of immunogenicity studies in some Asian countries, where the immune responses have been documented to be moderate in low-income countries with high diarrhoeal disease burden and mortality, and high in middle-/high-income countries with little reported rotavirus deaths. This review of these rotavirus clinical trials examines the results observed and attempts to draw lessons to inform decision-making, aid design of additional clinical trials and guide vaccine development by local manufacturers.

摘要

轮状病毒死亡率最高的地区是亚太地区，而轮状病毒疫苗在此地区可能产生巨大影响。然而，减毒活口服轮状病毒疫苗已在一些亚洲国家进行了少数免疫原性研究评估，这些国家的免疫反应记录在腹泻疾病负担和死亡率高的低收入国家为中等/高，在报告的轮状病毒死亡率低的中/高收入国家为高。对这些轮状病毒临床试验的回顾检查了观察到的结果，并试图吸取经验教训，为决策提供信息，帮助设计额外的临床试验，并指导当地制造商开发疫苗。